All News

mediterraneansandwich-498379__180.jpg

Dietary Improvement in Psoriatic Arthritis

d Jack Cush, MD

The results of the DIETA trial showed that dietary changes may control psoriatic arthritis (PsA) disease activity, independent of weight loss.  

Read Article
TNR,PSA,journal,0412

Now Available: TNR - Psoriatic Arthritis Journal Club

d Jack Cush, MD

A recording of this week’s Tuesday Night Rheumatology is now available. This outstanding webinar featured a robust discussion of the EXCEED study and Discover-2 trial, with Drs. Philip Mease, Peter Nash, Jack Cush and Rachel Tate.

Read Article
RheumNow Podcast square

Male vs. Female Responders (4.15.2022)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal Reports from the past week on RheumNow.com - including fellowship COVID-19 concerns, the limits of T2T in gout and the real odds of RA remission with your first biologic. 

Read Article
child.guttate.psoriasis

Kids With Psoriasis Maintained with Long Term IL-17A Inhibitor

d MedPage Today

Pediatric patients with moderate-to-severe plaque psoriasis obtained significant improvement in disease status for as long as 2 years with the interleukin (IL)-17A inhibitor ixekizumab (Taltz), long-term follow-up from a randomized trial showed.

Read Article
uric%20acid.crystals.gout_.JPG

No Benefit to More Intensive Urate Lowering in Gout

d Jack Cush, MD

While treat-to-target (T2T) is commonly advocated in gout management, it is unknown if T2T (or more intensive T2T) may result in less bony erosions in gout.

Read Article
Can IL-22 differentiate between IL-17 & TNF inhibitor #PSA responders? Pilot study 2 cohorts 81 PSA pts showed both biologics worked but somewhat better response in IL-17i Pts w/ low IL- & TNFi responses w/ high IL-22 levels. https://t.co/txyNl2OwTP

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Copenhagen study of COVID & Rheum disease (AIRD) ▶️ COVID+ AIRD pts have 10x more hospitalizations (7% vs 0.7%) ▶️ Only RTX assoc w/ COVID hosp (adj OR 14.6) ▶️ IgG Abs increased if AIRD pt hospitalized https://t.co/VtERRZsGb8 https://t.co/ZwdfNJaAS7

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Males respond better than females? Ixekizumab trials in #PSA - 676 pts in Two Phase 3 RCTs - females had lower response rates than males in all measures (ACR20/50/70; MDA; DAPSA) F had ⬆️HAQ, enthesitis, but ⬇️CRP https://t.co/sjVJZ8uQA3 https://t.co/l7B2ICZWaJ

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: SLE study from BC, Canada shows that among 3062 incident #SLE patients 96% received antimalarial (AM) Rx with only 40% adherent. Over a 6.4 yr F/U, 242 (8%) died. AM adherence was assoc w/ a 71% and 83% lower risk of death https://t.co/0uKAKJVxri https://t.co/KuvEA2pzrg

Links:

Dr. John Cush RheumNow ( View Tweet)
In #rheumatology ,the longer you see pts,the more they rely on you for issues related to their disease, including ➡️ Dental/mental Health ➡️ Nutrition/exercise/sleep ➡️ PT/OT/rehab Looking for resources pertaining to rheumatology to self educate. #RheumTwitter #MedTwitter

Tanmayee Bichile, MD BichileT ( View Tweet)

Register for Tuesday Night Rheumatology today! Join us as we discuss the controversies in PsA when it comes to diagnosis, treatment strategies, therapeutics and more. https://t.co/YXAmzvPfeK https://t.co/jtSd0Ig5IT

Links:

Dr. John Cush RheumNow ( View Tweet)
Administrative Claims data from British Columbia studied 100,358 OA pts and compared tramadol v NSAIDs. Tramadol was associated with higher All-cause mortality (HRs,1.2 to 1.5), more VTE (v diclofenac, HR 1.7), more hip Fx (HR 1.6) https://t.co/5Lei6Lgtpf

Links:

Dr. John Cush RheumNow ( View Tweet)

Kids With Psoriasis Maintained with Long Term IL-17A Inhibitor https://t.co/CfAjvc9XWg https://t.co/RaD5qqPM3a

Links:

Dr. John Cush RheumNow ( View Tweet)
No Benefit to More Intensive Urate Lowering in Gout While treat-to-target (T2T) is commonly advocated in gout management, it is unknown if T2T (or more intensive T2T) may result in less bony erosions in gout. https://t.co/uag4fJ4FSi https://t.co/djniwFl491

Links:

Dr. John Cush RheumNow ( View Tweet)
Copenhagen study of COVID & Rheum disease (AIRD) ▶️ COVID+ AIRD pts have 10x more hospitalizations (7% vs 0.7%) ▶️ Only RTX assoc w/ COVID hosp (adj OR 14.6) ▶️ IgG Abs increased if AIRD pt hospitalized https://t.co/WYXbt2FJJi https://t.co/K2NGJsKVVc

Links:

Dr. John Cush RheumNow ( View Tweet)
Large metanalysis looks at Quality of Life outcomes w/ Therapies in #PSA 37 RCTs = 14.115 PsA pts ◾️ bDMARDs > PBO ◾️ bDMARDs = MTX (or Tofa) ◾️ bDMARDs + MTX > MTX https://t.co/6DDsVjcdcr https://t.co/ljb6AOH3UK

Links:

Dr. John Cush RheumNow ( View Tweet)
Downward Effects! Real world data from 22,934 UK #RA pts starting 1st b/tsDMARD shows DAS remission/LDA achieved in 17% following 1st line, 13% 2nd, & 8-13% with 3rd thru 6th DMARD. (LDA in 29% 1st line, 23% 2nd, 17–22% 3rd thru 6th) https://t.co/cZt0BvhK6I https://t.co/blemgbDoN8

Links:

Dr. John Cush RheumNow ( View Tweet)
Despite COVID, revenues for half of top 20 pharma companies grew 10-40% in 2021 Revenues (billions) 1 J&J $97 2 Pfizer $81 3 Roche $62 4 Abbvie $56 5 Novartis $51 6 Merck $48 7 BMS $46 8 GSK $46 9 Sanofi $44 10 AZ $37 https://t.co/rSovxIXOId https://t.co/GuKIBYoML6

Links:

Dr. John Cush RheumNow ( View Tweet)
Males respond better than females? Ixekizumab trials in #PSA - 676 pts in Two Phase 3 RCTs - females had lower response rates than males in all measures (ACR20/50/70; MDA; DAPSA) F had ⬆️HAQ, enthesitis, but ⬇️CRP https://t.co/Om8CwbmlgN https://t.co/872E7HGOp2

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - PsA Lessons from the Clinic LFT Elevations may be considered differently in PsA patients QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022 https://t.co/dCaWx5OTda https://t.co/bRTVqQ4ZJj

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×